SK285074B6 - Spôsob izolácie a čistenia inhibítorov HMG-CoA - Google Patents

Spôsob izolácie a čistenia inhibítorov HMG-CoA Download PDF

Info

Publication number
SK285074B6
SK285074B6 SK1185-2000A SK11852000A SK285074B6 SK 285074 B6 SK285074 B6 SK 285074B6 SK 11852000 A SK11852000 A SK 11852000A SK 285074 B6 SK285074 B6 SK 285074B6
Authority
SK
Slovakia
Prior art keywords
hmg
coa reductase
water
reductase inhibitor
crystallization
Prior art date
Application number
SK1185-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK11852000A3 (sk
Inventor
Zlatko Pflaum
Du�an Milivojevi�
David Senica
Original Assignee
Lek Pharmaceutical And Chemical Company D. D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285074(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceutical And Chemical Company D. D. filed Critical Lek Pharmaceutical And Chemical Company D. D.
Publication of SK11852000A3 publication Critical patent/SK11852000A3/sk
Publication of SK285074B6 publication Critical patent/SK285074B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
SK1185-2000A 1998-02-18 1999-02-17 Spôsob izolácie a čistenia inhibítorov HMG-CoA SK285074B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800046A SI9800046A (sl) 1998-02-18 1998-02-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
PCT/IB1999/000808 WO1999042601A1 (fr) 1998-02-18 1999-02-17 PROCEDE D'OBTENTION D'INHIBITEURS TRES PURS DE LA HMG-CoA REDUCTASE

Publications (2)

Publication Number Publication Date
SK11852000A3 SK11852000A3 (sk) 2001-05-10
SK285074B6 true SK285074B6 (sk) 2006-05-04

Family

ID=20432203

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1185-2000A SK285074B6 (sk) 1998-02-18 1999-02-17 Spôsob izolácie a čistenia inhibítorov HMG-CoA

Country Status (21)

Country Link
US (1) US6825015B1 (fr)
EP (1) EP1054993B1 (fr)
JP (2) JP2002504345A (fr)
KR (1) KR100582620B1 (fr)
CN (1) CN1206363C (fr)
AT (1) ATE296357T1 (fr)
AU (1) AU743619B2 (fr)
BG (1) BG64289B1 (fr)
CA (1) CA2321052A1 (fr)
CZ (1) CZ297093B6 (fr)
DE (1) DE69925459T2 (fr)
HR (1) HRP20000541A2 (fr)
HU (1) HUP0100820A3 (fr)
IL (1) IL137782A0 (fr)
PL (1) PL193510B1 (fr)
RO (1) RO120922B1 (fr)
RU (1) RU2235130C2 (fr)
SI (2) SI9800046A (fr)
SK (1) SK285074B6 (fr)
WO (1) WO1999042601A1 (fr)
YU (1) YU50100A (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005283A (es) * 1999-11-30 2003-10-06 Biogal Gyogyszergyar Proceso para recuperar compuestos estatina de un caldo de fermentacion.
KR20020062340A (ko) 1999-12-14 2002-07-25 비오갈 기오기스제르갸르 알티. 신규 형태의 프라바스타틴 나트륨
WO2001062949A1 (fr) * 2000-02-24 2001-08-30 Biogal Gyogyszergyar Rt Procede de purification de jus de fermentation
TR200403001T3 (tr) 2000-03-03 2005-02-21 Plus Chemical, S.A. Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem
IN192861B (fr) * 2000-06-30 2004-05-22 Ranbaxy Lab Ltd
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
WO2005051372A2 (fr) 2003-11-24 2005-06-09 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Procédé de purification de pravastatine
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
CN102384955B (zh) * 2010-09-01 2014-04-30 北京北大维信生物科技有限公司 人体血浆中HMG－CoA还原酶抑制剂的定量分析方法
RU2585234C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Способ получения компактина
RU2585233C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Промышленный способ получения компактина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294846A (en) * 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
ATE189804T1 (de) * 1995-08-03 2000-03-15 Dsm Nv Selektives verfahren zur deacylierung von acylverbindungen
CA2243592C (fr) * 1995-12-06 2001-12-25 Antibiotic Co. Procede de production de lovastatine
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására

Also Published As

Publication number Publication date
WO1999042601A1 (fr) 1999-08-26
HRP20000541A2 (en) 2001-12-31
KR100582620B1 (ko) 2006-05-23
SI1054993T1 (en) 2005-10-31
PL193510B1 (pl) 2007-02-28
CA2321052A1 (fr) 1999-08-26
JP2005110693A (ja) 2005-04-28
CN1291238A (zh) 2001-04-11
BG64289B1 (bg) 2004-08-31
SI9800046A (sl) 1999-08-31
RO120922B1 (ro) 2006-09-29
ATE296357T1 (de) 2005-06-15
YU50100A (sh) 2003-07-07
PL342513A1 (en) 2001-06-18
SK11852000A3 (sk) 2001-05-10
IL137782A0 (en) 2001-10-31
CZ20002856A3 (cs) 2000-11-15
HUP0100820A3 (en) 2003-07-28
AU3438499A (en) 1999-09-06
DE69925459T2 (de) 2006-04-27
BG104696A (en) 2001-07-31
RU2235130C2 (ru) 2004-08-27
EP1054993B1 (fr) 2005-05-25
KR20010041024A (ko) 2001-05-15
JP2002504345A (ja) 2002-02-12
DE69925459D1 (de) 2005-06-30
US6825015B1 (en) 2004-11-30
EP1054993A1 (fr) 2000-11-29
CZ297093B6 (cs) 2006-09-13
HUP0100820A2 (hu) 2001-08-28
AU743619B2 (en) 2002-01-31
CN1206363C (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
SK285074B6 (sk) Spôsob izolácie a čistenia inhibítorov HMG-CoA
AU2001236543B2 (en) Method of purifying a fermentation broth
WO2001030773A2 (fr) Procede de lactonisation
JP3236282B1 (ja) プラバスタチンを精製する方法
CN1238776A (zh) 制备棒酸盐和酯的方法
SK4522003A3 (en) Method of purifying pravastatin or its pharmacologically acceptable salt
US6767998B2 (en) Method for preparing purified erythromycin
ES2204285B1 (es) Procedimiento para el aislamiento y purificacion de lovastatina.
JP2002128739A (ja) プラバスタチンを精製する方法

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130217